{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:13Z","timestamp":1787003773823,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12333-8","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T08:22:03Z","timestamp":1753777323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blood platelet reduction after elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction"],"prefix":"10.1038","volume":"15","author":[{"given":"Alice","family":"Castaldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cimbalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Carnovale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Iacotucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Raia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gelzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"12333_CR1","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMe1712335","volume":"377","author":"H Grasemann","year":"2017","unstructured":"Grasemann, H. CFTR modulator therapy for cystic fibrosis. N. Engl. J. Med. 377, 2085\u20132088 (2017).","journal-title":"N. Engl. J. Med."},{"key":"12333_CR2","doi-asserted-by":"publisher","first-page":"175346662513231","DOI":"10.1177\/17534666251323194","volume":"19","author":"V Terlizzi","year":"2025","unstructured":"Terlizzi, V. & Lopes-Pacheco, M. Cystic fibrosis: New challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor. Ther. Adv. Respir. Dis. 19, 17534666251323194 (2025).","journal-title":"Ther. Adv. Respir. Dis."},{"key":"12333_CR3","volume":"54","author":"V Terlizzi","year":"2024","unstructured":"Terlizzi, V. & Farrell, P. M. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians. Curr. Probl. Pediatr. Adolesc. Health Care. 54, 101637 (2024).","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care."},{"key":"12333_CR4","doi-asserted-by":"publisher","first-page":"10358","DOI":"10.3390\/ijms241210358","volume":"24","author":"K Kleinfelder","year":"2023","unstructured":"Kleinfelder, K. et al. Theratyping of the rare CFTR genotype A559T in rectal organoids and nasal cells reveals a relevant response to Elexacaftor (VX-445) and Tezacaftor (VX-661) combination. Int. J. Mol. Sci. 24, 10358 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"12333_CR5","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/humu.23741","volume":"40","author":"F Amato","year":"2019","unstructured":"Amato, F. et al. Two CFTR variants within codon 970 differently impact on the chloride channel functionality. Hum. Mutat. 40, 742\u2013748 (2019).","journal-title":"Hum. Mutat."},{"key":"12333_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1656","volume":"9","author":"V Terlizzi","year":"2021","unstructured":"Terlizzi, V. et al. Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol. Genet. Genomic Med. 9, e1656 (2021).","journal-title":"Mol. Genet. Genomic Med."},{"key":"12333_CR7","doi-asserted-by":"publisher","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","volume":"62","author":"E Dreano","year":"2023","unstructured":"Dreano, E. et al. Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription. Eur. Respir. J. 62, 2300110 (2023).","journal-title":"Eur. Respir. J."},{"key":"12333_CR8","doi-asserted-by":"publisher","first-page":"10239","DOI":"10.1016\/j.coph.2022.102239","volume":"65","author":"KA Despotes","year":"2022","unstructured":"Despotes, K. A. & Donaldson, S. H. Current state of CFTR modulators for treatment of cystic fibrosis. Curr. Opin. Pharmacol. 65, 10239 (2022).","journal-title":"Curr. Opin. Pharmacol."},{"key":"12333_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/ph16030410","volume":"16","author":"M Bacalhau","year":"2023","unstructured":"Bacalhau, M. et al. Elexacaftor-Tezacaftor-Ivacaftor: a life-changing triple combination of CFTR modulator drugs for Cystic Fibrosis. Pharmaceuticals (Basel) 16, 410 (2023).","journal-title":"Pharmaceuticals (Basel)"},{"key":"12333_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","volume":"206","author":"SY Graeber","year":"2022","unstructured":"Graeber, S. Y. et al. Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles. Am. J. Respir. Crit. Care Med. 206, 311\u2013320 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"12333_CR11","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.jcf.2021.11.006","volume":"21","author":"K McBennett","year":"2022","unstructured":"McBennett, K. et al. Magnetic resonance imaging of cystic fibrosis: multi-organ imaging in the age of CFTR modulator therapies. J. Cyst. Fibros. 21, e148\u2013e157 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","volume":"22","author":"C Steinack","year":"2023","unstructured":"Steinack, C. et al. Improved glucose tolerance after initiation of Elexacaftor \/ Tezacaftor \/ Ivacaftor in adults with cystic fibrosis. J. Cyst. Fibros. 22, 722\u2013729 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR13","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman, H. G. M. et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del variant: a double-blind, randomised, phase 3 trial. Lancet 394, 1940\u20131948 (2019).","journal-title":"Lancet"},{"key":"12333_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","volume":"11","author":"V Carnovale","year":"2022","unstructured":"Carnovale, V. et al. Elexacaftor\/Tezacaftor\/Ivacaftor in patients with Cystic Fibrosis homozygous for the F508del variant and advanced lung disease: a 48-week observational study. J. Clin. Med. 11, 1021 (2022).","journal-title":"J. Clin. Med."},{"key":"12333_CR15","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick, E. T. et al. A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am. J. Respir. Crit. Care Med. 203, 1522\u20131532 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"12333_CR16","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/ppul.27125","volume":"59","author":"V Dacc\u00f2","year":"2024","unstructured":"Dacc\u00f2, V. et al. Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in children aged 6\u201311 years with cystic fibrosis in a real-world setting. Pediatr. Pulmunol. 59, 2792\u20132799 (2024).","journal-title":"Pediatr. Pulmunol."},{"key":"12333_CR17","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"12333_CR18","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/jcm11236900","volume":"11","author":"V Carnovale","year":"2022","unstructured":"Carnovale, V. et al. Cystic Fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment. J. Clin. Med. 11, 6900 (2022).","journal-title":"J. Clin. Med."},{"key":"12333_CR19","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","volume":"21","author":"S Lowry","year":"2022","unstructured":"Lowry, S., Mogayzel, P. J., Oshima, K. & Karnsakul, W. Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor. J. Cyst. Fibros. 21, e99\u2013e101 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jcf.2023.06.013","volume":"22","author":"V Terlizzi","year":"2023","unstructured":"Terlizzi, V. et al. Hyperbilirubinemia and Gilbert\u2019s syndrome in Cystic Fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor. J. Cyst. Fibros. 22, 1130\u20131132 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR21","doi-asserted-by":"publisher","first-page":"1327958","DOI":"10.3389\/fmolb.2023.1327958","volume":"10","author":"A Castaldo","year":"2024","unstructured":"Castaldo, A. et al. One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del variant causes a significant increase in liver biochemical indexes. Front. Mol. Biosci. 10, 1327958 (2024).","journal-title":"Front. Mol. Biosci."},{"key":"12333_CR22","doi-asserted-by":"publisher","first-page":"17422","DOI":"10.1038\/s41598-024-68511-7","volume":"14","author":"A Castaldo","year":"2024","unstructured":"Castaldo, A. et al. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/Ivacaftor treatment. Sci. Rep. 14, 17422 (2024).","journal-title":"Sci. Rep."},{"key":"12333_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245302","volume":"16","author":"F Amato","year":"2021","unstructured":"Amato, F. et al. Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A Preliminary study. PLoS One 16, e0245302 (2021).","journal-title":"A Preliminary study. PLoS One"},{"key":"12333_CR24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","volume":"206","author":"MA Mall","year":"2022","unstructured":"Mall, M. A. et al. Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 206, 1361\u20131369 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"12333_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","volume":"208","author":"JL Goralski","year":"2023","unstructured":"Goralski, J. L. et al. Phase 3 open label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele. Am. J. Respir. Crit. Care Med. 208, 59\u201367 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"12333_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2024.114176","volume":"274","author":"V Terlizzi","year":"2024","unstructured":"Terlizzi, V. et al. Reported adverse events in a multicenter cohort of patients ages 6\u201318 years with cystic fibrosis and at least one F508del allele receiving elexacaftor\/tezacaftor\/ivacaftor. J. Pediatr. 274, 114176 (2024).","journal-title":"J. Pediatr."},{"key":"12333_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000010","volume":"7","author":"S Levitte","year":"2023","unstructured":"Levitte, S., Fuchs, Y., Wise, R. & Sellers, Z. M. Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis. Hepatol. Commun. 7, e0010 (2023).","journal-title":"Hepatol. Commun."},{"key":"12333_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","volume":"22","author":"DH Tewkesbury","year":"2023","unstructured":"Tewkesbury, D. H., Athwal, V., Bright-Thomas, R. J., Jones, A. M. & Barry, P. J. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre. J. Cyst. Fibros. 22, 256\u2013262 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR29","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1002\/ppul.26673","volume":"58","author":"T Manciulli","year":"2023","unstructured":"Manciulli, T. et al. Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor: experience of the regional center in Tuscany. Italy. Ped. Pulmunol. 58, 3626\u20133629 (2023).","journal-title":"Italy. Ped. Pulmunol."},{"key":"12333_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1160\/TH14-12-1067","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas, M. R. & Storey, R. F. The role of platelets in inflammation. Thromb. Haemost. 114, 449\u2013458 (2015).","journal-title":"Thromb. Haemost."},{"key":"12333_CR31","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.4049\/jimmunol.1900899","volume":"203","author":"A Margraf","year":"2019","unstructured":"Margraf, A. & Zarbock, A. Platelets in inflammation and resolution. J. Immunol. 203, 2357\u20132367 (2019).","journal-title":"J. Immunol."},{"key":"12333_CR32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3748\/wjg.15.591","volume":"15","author":"T Alempijevic","year":"2009","unstructured":"Alempijevic, T. et al. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J. Gastroenterol. 15, 591\u2013594 (2009).","journal-title":"World J. Gastroenterol."},{"key":"12333_CR33","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/jgh.12613","volume":"29","author":"A Avihingsanon","year":"2014","unstructured":"Avihingsanon, A. et al. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase\/platelet ratio index among asian hepatitis C with and without human immunodeficiency virus infection: Role of vitamin D levels. J. Gastroenterol. Hepatol. 29, 1706\u20131714 (2014).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"12333_CR34","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","volume":"79","author":"ZM Sellers","year":"2024","unstructured":"Sellers, Z. M. et al. Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations. Hepatology 79, 1220\u20131238 (2024).","journal-title":"Hepatology"},{"key":"12333_CR35","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jcf.2023.09.009","volume":"22","author":"KW Southern","year":"2023","unstructured":"Southern, K. W. et al. Standards for the care of people with CF. J. Cyst. Fibros. 22, 961\u2013962 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1515\/cclm-2017-0553","volume":"56","author":"A Bergougnoux","year":"2018","unstructured":"Bergougnoux, A. et al. Multicenter validation study for the certification of a CFTR gene scanning method using next generation sequencing technology. Clin. Chem. Lab. Med. 56, 1046\u20131053 (2018).","journal-title":"Clin. Chem. Lab. Med."},{"key":"12333_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower, J. K. et al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. J. Cyst. Fibros. 22, 730\u2013737 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR38","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jcf.2020.05.002","volume":"19","author":"W Karnsakul","year":"2020","unstructured":"Karnsakul, W. et al. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease. J. Cyst. Fibros. 19, 546\u2013552 (2020).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21861","volume":"9","author":"JA Scott","year":"2023","unstructured":"Scott, J. A. et al. Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools. Heliyon 9, e21861 (2023).","journal-title":"Heliyon"},{"key":"12333_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.12.010","author":"V Terlizzi","year":"2025","unstructured":"Terlizzi, V. et al. Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis. J. Cyst. Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2024.12.010 (2025).","journal-title":"J. Cyst. Fibros."},{"key":"12333_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/17534666251314706","author":"A Pepe","year":"2025","unstructured":"Pepe, A. et al. Elexacaftor\/Tezacaftor\/Ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual center cohort study. Ther. Adv. Chron. Dis. https:\/\/doi.org\/10.1177\/17534666251314706 (2025).","journal-title":"Ther. Adv. Chron. Dis."},{"key":"12333_CR42","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","volume":"207","author":"A Lepissier","year":"2023","unstructured":"Lepissier, A. et al. Moving the dial on airway inflammation in response to Trikafta in adolescents with cystic fibrosis. Am. J. Respir. Crit. Care Med. 207, 792\u2013795 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"12333_CR43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","volume":"205","author":"C Gabillard-Lefort","year":"2022","unstructured":"Gabillard-Lefort, C. et al. Trikafta Rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 205, 783\u2013794 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"12333_CR44","doi-asserted-by":"publisher","first-page":"L905","DOI":"10.1152\/ajplung.00272.2024","volume":"327","author":"TH Hampton","year":"2024","unstructured":"Hampton, T. H. et al. Gene expression responses of CF airway epithelial cells exposed to elexacaftor\/tezacaftor\/ivacaftor suggest benefits beyond improved CFTR channel function. Am. J. Physiol. Lung Cell. Mol. Physiol. 327, L905\u2013L916 (2024).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"12333_CR45","doi-asserted-by":"publisher","first-page":"1180282","DOI":"10.3389\/fimmu.2023.1180282","volume":"14","author":"H Schmidt","year":"2023","unstructured":"Schmidt, H. et al. Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after elexacaftor-tezacaftor-ivacaftor treatment. Front. Immunol. 14, 1180282 (2023).","journal-title":"Front. Immunol."},{"key":"12333_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/COPD.S152660","volume":"13","author":"M Mu\u00f1oz-Esquerre","year":"2017","unstructured":"Mu\u00f1oz-Esquerre, M. et al. Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 141\u2013148 (2017).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"12333_CR47","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jpn3.12167","volume":"78","author":"L Aitokari","year":"2024","unstructured":"Aitokari, L., Hiltunen, P., Huhtala, H., Kurppa, K. & Kivel\u00e4, L. Measurement practices of alanine aminotransferase in children: Temporal changes and etiology for increased values. J. Pediatr. Gastroenterol. Nutr. 78, 1383\u20131388 (2024).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"12333_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.amjcard.2020.10.036","volume":"139","author":"D Maeda","year":"2021","unstructured":"Maeda, D. et al. Relation of Aspartate Aminotransferase to Alanine Aminotransferase Ratio to Nutritional Status and Prognosis in Patients With Acute Heart Failure. Am. J. Cardiol. 139, 64\u201370 (2021).","journal-title":"Am. J. Cardiol."},{"key":"12333_CR49","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/jac\/dkr159","volume":"66","author":"RJ Andrade","year":"2011","unstructured":"Andrade, R. J. & Tulkens, P. M. Hepatic safety of antibiotics used in primary care. J. Antimicrob. Chemother. 66, 1431\u20131446 (2011).","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12333-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:59:29Z","timestamp":1757311169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12333-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12333"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12333-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical committee of the CF regional Centre of Tuscany (Ethics Clearance number 63\/2023) and of Campania (Ethics Committee number 77\/2021). Informed consent was obtained from all participants or the legal guardian\/next relative of the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"27571"}}